

UnitedHealthcare Pharmacy
Clinical Pharmacy Programs

Program Number	2025 P 1442-2
Program	Prior Authorization/Notification
Medication	Filsuvez® (birch triterpenes) topical gel
P&T Approval Date	4/2024, 4/2025
Effective Date	7/1/2025

1. Background:

Filsuvea (birch triterpenes) topical gel is indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa in adult and pediatric patients 6 months of age and older.

2. Coverage Criteria^a:**A. Initial Authorization****1. Filsuvez will be approved based on all of the following criteria:**

- a. Patient is at least 6 months of age and older

-AND-

- b. **One** of the following diagnoses:

- (1) Dystrophic epidermolysis bullosa (DEB)

-OR-

- (2) Junctional epidermolysis bullosa (JEB)

-AND-

- c. Patient is **not** receiving Filsuvez in combination with Vyjuvek (beremagene geperpavec-svdt) on the same wound(s)

Authorization will be issued for 12 months.

2. Reauthorization

- a. **Filsuvez** will be approved based **all** of the following criteria:

- (1) Documentation of positive clinical response to therapy

-AND-

- (2) Patient is **not** receiving Filsuvez in combination with Vyjuvek (beremagene geperpavec-svdt) on the same wound(s)

Authorization will be issued for 12 months.

^a State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management programs may apply.

3. Additional Clinical Rules:

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.
- Supply limits may be in place.

4. References:

1. Filsuvez [package insert]. Boston, MA: Chiesi Global Rare Diseases; May 2024.

Program	Prior Authorization/Notification - Filsuvez (birch triterpenes)
Change Control	
4/2024	New program.
4/2025	Annual review with no changes to criteria. Updated references.